Phenomenological analysis of the clotting curve

A model-independent (phenomenological) characterization of the clotting curve is proposed. Three parameters are used to encapsulate the main features of the increase in absorbance observed at 350 nm due to the reaction of thrombin with fibrinogen that leads to clot formation: (1) the maximum increase in absorbance per unit time, A _m , at the inflection point of the clotting curve; (2) the time needed to reach the maximum increase in absorbance,t _m ; and (3) the clotting time,t _c , obtained from extrapolation of the slope att _m to the zero absorbance baseline. Clotting curves at low fibrinogen concentrations (0.125 ÷ 0.250 µM), well below the K_m, where thrombin amidase activity is rate-limiting with respect to the subsequent aggregation process, have been measured under a wide variety of experimental conditions, (i.e., as a function of thrombin concentration,pH and temperature) in order to explore the basic response of each parameter to changes in solution conditions. Under all conditions examined in this study we have observed thatt _m andt _c are linked through a linear relationship that appears to be an important invariant property of the clotting curve, regardless of experimental conditions. No such clear relationship exists between A _m andt _c , witht _c being associated with several possible values of A _m and vice versa, depending upon solution conditions. It is proposed thatt _c is strictly dependent on thrombin amidase activity, while A _m reflects properties of the aggregation process leading to clot formation. The clotting time shows apH and temperature dependence that closely resembles that of K_m/V_m for synthetic amide substrates. Futhermore,t _c changes linearly with either the inverse thrombin concentration and the concentration of competitive inhibitors of fibrinogen binding to thrombin, as expected for the ratio K_m/V_m. We show how the analysis of clotting curves obtained at different thrombin and inhibitor concentrations yields a quantitative measure of K_I that is in excellent agreement with the value determined independently from steady-state measurements of thrombin amidase activity.     

Molecular mechanisms of the shrimp clotting system

Shrimp, like other invertebrates, relies solely on its innate immune system, to combat invading pathogens. The invertebrate immune system has ancient origins that involve cellular and humoral responses. The clotting system of the humoral immune response is the first line of defense against pathogens and also serves to prevent blood loss during injury and wound healing. Tranglutaminase and clotting protein are molecules involved in the blood clotting system of crayfish and shrimp. Studies have shown that the shrimp clotting system is linked with the activation of antimicrobial peptides, similar to that of the horseshoe crab. Unlike the horseshoe crab and crayfish blood coagulation which are well studied systems, blood clotting in shrimp remains poorly understood. Here we review the shrimp clotting system and its involvement in innate immunity.     

Cross induced coagulations between human and crustacean clotting factors. Considerations on the clotting processes

1. Cross induced coagulations show that human factor XIII and crustacean coagulin are to some extent functionally equivalent and may be substituted for each other. 2. In crustacea, fibrinogen and coagulin appear as in situ activated products since they are both able to react with non-activated human clotting factors. 3. The coagulin catalyzed transamidation which stabilizes the clot and renders it insoluble in 1-5% monochloroacetic acid solutions seems to be the basic reaction of the clotting process in the animals in which coagulation occurs. 4. The possibility of a two step clotting in crustacea is discussed.     

On enzymic clotting processes V: Rate equations for the case of arbitrary rate of production of the clotting species

The rate theory for enzyme-triggered coagulation reactions, such as the clotting of fibrin or casein, is extended to the case of an arbitrary rate of production of the clotting species. It is shown that the general expression for the growth of the weight-average molecular weight of the clotting product, -M_w, is given by -M_w = M₁{1 + k_s {∫₀^tP(t)² dt}/P(t)}, where M₁ is the “monomer” molecular weight, k_s the smoluchowskian flocculation rate constant and P(t) the total number of monomers produced by the enzyme in t. In the purely smoluchowskian case P(t) stands for the total number of monomers at the beginning of the clotting process. Numerical examples in which the rate of enzymic production is governed by complete Michaelis-Menten kinetics, are compared to cases in which this rate equals V_max- It is shown that after exhaustion of the substrate the system continues to coagulate in a purely smoluchowskian way. Turbidimetric experiments on the clotting of micelles of whole and κ-casein are presented which suggest inactivation of the enzyme by non-productive binding in the flocs formed.     

Blood clotting in space

We describe herein a novel in vitro approach that can be used effectively to obtain valuable insights into the role of platelets, various coagulation proteins as well as proteins of the subendothelial extracellular matrix involved in the hemostatic and thrombotic processes occurring under microgravity. At difference with other experimental approaches proposed in the past our device operates in a closed system and under different shear forces, which better mimics flow conditions occurring in vessels. Furthermore our device by allowing real time monitoring of the thrombotic process and its underlying mechanisms can be regarded as a reliable system for the precise assessment of platelet function.     

Transglutaminases and the clotting of mammalian seminal fluids

Summary Rapid coagulation of seminal fluid in rats, guinea pigs, and several other mammalian species including certain non-human primates is responsible for the post-coital formation of copulatory plugs in the vagina. The clotting of rodent seminal plasma results from coagulation of certain proteins derived from the seminal vesicles by enzymes secreted mainly by the coagulating (anterior prostate) gland. Several lines of evidence indicate that the clotting enzymes of coagulating gland secretions are trans glutaminases, and that the extreme insolubility of the seminal clot in rodents is due to transglutaminase-catalyzed formation of (-glutamyl)ly-sine cross-links between polypeptide chains. Various features of the apparently unique forms of transglutaminases produced by rat coagulating gland and the actions of these enzymes on vesicular secretory and other proteins are discussed. The aliphatic polyamines spermidine and spermine are incorporated covalently into the proteins of the clot as the corresponding N-mono--(-glutamyl)- and N,N-bis(-glutamyl)-adducts during the enzymatic coagulation process. At the greater than millimolar concentrations at which cross-spermidine and spermine are present in normal rat seminal plasma, these polyamines attenuate the formation of hard clots in reconstituted rat semen coagulation systems, seemingly by competing with lysyl residues in vesicular secretion proteins as transglutaminase amine donor substrates, and thus preventing formation of -(-glutamyl)lysine cross-bridges. It is proposed that in those species such as the rat and man in which seminal plasma contains large amounts of spermidine and(or) spermine of prostatic origin, the seminal polyamines may serve to stop blockage of the urethra by preventing too explosive a rate of seminal clot formation during the ejaculatory process.     

Counteracting clotting in sepsis

The complexity of factors that regulate bleeding and coagulation has long confounded researchers. Andrew Wei and Shaun Jackson help clear the air by examining clinical findings pointing to a mechanistic basis for a common bleeding disorder, immune thrombocytopenic purpura. Mark Kahn tackles two research studies that could lead to improved therapies for a coagulation syndrome that hits people with severe sepsis.